Newsletter | October 22, 2025

10.22.25 -- RNA Delivery Reimagined: The Players And The Strategy

SPONSOR

Unlocking The Future: Innovations in the mRNA & Oligo Supply Chains

Join Advancing RNA Chief Editor Anna Rose Welch and panelists for a forward-looking event exploring the current and next generation of raw materials shaping the mRNA and oligo therapeutics landscapes. Registration is free. Click here to learn more.

FEATURED EDITORIAL

RNA Delivery Reimagined: The Players And The Strategy

Kicking off a recent webinar, “RNA Delivery Reimagined: Innovative Non-Viral Strategies Beyond LNPs,” leaders from Nanite Bio, nChroma Bio, Nosis Bioresearch, and Aegle Therapeutics share how their teams are pushing RNA delivery beyond LNPs — exploring polymer-based systems, receptor-targeted conjugates, engineered viral-like particles, and extracellular vesicles — to tackle challenges like cell specificity, off-target effects, and scalable manufacturing.

What You Should Know About USP's Bioassay Updates

The United States Pharmacopeia is overhauling general chapters to align them with current industry standards. One scientist on the project helps us unpack the changes.

INDUSTRY INSIGHTS

A Derivatization-Free LCMS Assay For 4Β-hydroxycholesterol

Learn about a novel LCMS assay for 4Β-hydroxycholesterol, a key biomarker for CYP3A activity. This derivatization-free method offers a faster and more efficient approach for clinical studies.

Five Questions Biotechs Should Ask Before Selecting A Bioanalytical CRO

In a landscape where speed, quality, and trust are inseparable, choosing a CRO that shares your ambition is not optional—it is essential to survival and success.

IR Spectral Signatures Of GC, AU, And GU Base Pairing By MMS

Explore a label-free approach to characterize RNA structure with high sensitivity. See how specific base pair types are resolved, providing a clearer picture of RNA folding.

Understanding mRNA Technology As A Platform For Biopharma

Explore the advantages of mRNA technology, the process steps of large-scale mRNA production, and the effect of common contaminants on mRNA manufacturing.

GMP Annex 1 For Sterile Manufacturing In The EU

The revised EU GMP Annex 1 mandates a comprehensive Contamination Control Strategy, continuous environmental monitoring, and species-level contaminant identification to ensure compliance.

A Risk-Based Approach To Plasmid DNA And mRNA Process Development

Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.

SOLUTIONS

Services For Advancing mRNA-LNPs From Bench To Clinic

TakeOne Aseptic Sampling System

Regulatory Strategy And Submission Support

Process Chemicals For RNA Drug Manufacturing